Jeito Capital is building a strong and diversified portfolio in Biotech and innovative medical companies.
Neogene TherapeuticsOncology - Cell Therapy
Round of €93 million
Sparing VisionOphtalmology - Gene Therapy
Round of €44,5 million
innoSkelRare bone Diseases - Gene Therapy
Round of €20 million
PulmocideInhaled Respiratory Medicine
Round of €75 million
Alentis TherapeuticsFibrotic Diseases Medicine
Round of €55 million
Quell TherapeuticsT-reg cell therapy in auto-immune and inflammatory diseases
Round of €138 million
NMD PharmaSevere neuromuscular diseases
Round of €35 million
EyeBioEye disease therapies
Round of $65 million
Round of €80 million
Round of $76 million
HI-BioAuto-Immune Diseases - Cell Therapy
Round of $120 million
Round of €50 million
Oncology – Cell therapy
Round of €93 million – September 2020
Negoene is a preclinical biotechnology company at the forefront of developing next-generation, fully personalized T-cell therapies targeting a wide range of cancers.
Ophtalmology – Gene Therapy
Round of €44,5 million – September 2020
SparingVision is specialized in the research and development of ophthalmic treatments, particularly in the field of hereditary retinal degeneration.
Rare bone diseases – Gene therapy
Round of €20 million – December 2020
Innoskel is a French Biotech company focused on the development of genetic therapies for rare skeletal diseases that can cause dwarfism and severe deformities.
Inhaled respiratory medicine
Round of €75 million – May 2021
Pulmocide is a UK-based Biotech developing a leading range of first-in-class inhaled anti-infectives for the targeted treatment of life-threatening lung infections.
Fibrotic diseases medicine
Round of €55 million – June 2021
Alentis Therapeutics is a Swiss-based Biotech with R&D activities in France that focuses on the development of highly innovative treatments for fibrotic diseases using monoclonal antibodies targeting Claudin-1.
T-reg cell therapy in auto-immune and inflammatory diseases
Round of €138 million – November 2021
Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.
Severe neuromuscular diseases
Round of €35 million – February 2022
NMD Pharma A/S, is a private Biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders. The Company was incorporated as a spin-off from Aarhus University, Denmark in 2015 and was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity.
Round of $65 million – February 2022
EyeBio is a newly launched global company developing the next generation of eye disease therapies
Founded by two pioneers in ophthalmology drug development to build and advance diversified pipeline of ocular therapies
Jeito selects EyeBio as its 8th investment and continues to build a strong & diversified portfolio of companies with groundbreaking therapies in areas of high unmet need
Round of €80 million – March 2022
Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology as its ninth investment.
The financing will allow Precirix to advance its pipeline of precision radiopharmaceuticals.
Round of $76 million – April 2022
CDR-Life is a Swiss Biotech company at the forefront of a new class of highly tumor-specific immuno-oncology therapeutics.
CDR-Life leverages the unique expertise and track record of its founders, who together have developed new approved drugs and entered into major biotechnology agreements.
Jeito chooses CDR-Life as its 10th investment and continues to build a strong and diversified portfolio of companies with breakthrough therapies in areas of unmet needs.
Auto-Immune Diseases – Cell Therapy
Round of $120 million – November 2022
Human Immunology Biosciences (HI-Bio) is a San Francisco-based Phase II clinical-stage Biopharma company, with European development activities.
HI-Bio develops targeted therapies for patients suffering from severe immune-mediated diseases (IMD). It has several late-stage clinical programmes and a strong translational platform, enabling it to address many diseases with unmet medical needs.
Round of €50 million – November 2022
CatalYm is a Phase II clinical-stage Biopharma company developing novel immunotherapies to fight cancer. It is based in Munich.
Its lead drug candidate, Visugromab, is a monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15), an inhibitor of immune cell infiltration into the tumor tissue.
At a glance